Varie
Minerva Neurosciences Announces Appointment of Dr. David Kupfer to Its Board of Directors
WALTHAM, Mass., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of David J. Kupfer, M.D. to its board of directors, effective immediately.
"Dr. Kupfer's globally recognized research in recurrent mood disorders has helped to expand the understanding of CNS diseases in many areas," said Remy Luthringer, Ph.D., president and chief executive officer of Minerva. "These include long-term treatment strategies, the pathogenesis of psychiatric disorders, and the relationship of these diseases to predictive biomarkers and biological pathways."
"Dr. Kupfer's extensive experience and insights into psychiatric research will play a vital role as Minerva advances toward pivotal clinical trials with a number of innovative CNS therapies designed to address a range of unmet needs," said Marc D. Beer, chairman of Minerva.
Dr. Kupfer is an international leader in psychiatry and psychiatric research who has authored more than 1,100 articles, books and book chapters. He chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which defines the criteria for the diagnosis and classification of mental disorders. Dr. Kupfer received his M.D. from Yale University in 1965. He is Distinguished Professor emeritus of Psychiatry at the University of Pittsburgh School of Medicine, where he chaired that department for 26 years. As director of research at Western Psychiatric Institute and Clinic (WPIC), Dr. Kupfer helped establish WPIC as one of the nation's preeminent university-based psychiatric research centers. He is founding president of the International Society of Bipolar Disorders and was elected to the National Academy of Medicine (formerly the Institute of Medicine) in 1990.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in Phase IIb development for the treatment of schizophrenia; MIN-202, in Phase IIa and Phase Ib development for primary insomnia and comorbid insomnia, respectively; MIN-117, in Phase IIa development for the treatment of major depressive disorder; and MIN-301, in pre-clinical development for the treatment of Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market where it trades under the symbol "NERV". For more information, please visit:
www.minervaneurosciences.com/ .
www.minervaneurosciences.com
Copyright GlobeNewswire
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire